Blood–brain barrier permeability and tPA-mediated neurotoxicity
暂无分享,去创建一个
Anwar Rayan | D. Cines | A. Higazi | S. Yarovoi | T. Nassar | A. Rayan | Douglas B. Cines | Taher Nassar | Rami Abu Fanne | Sergei Yarovoi | Itschak Lamensdorf | Michael Karakoveski | Polianski Vadim | Mahmud Jammal | Abd Al-Roof Higazi | I. Lamensdorf | R. A. Fanne | Mahmud Jammal | Michael Karakoveski | Polianski Vadim
[1] W. Armstead,et al. Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. , 2005, Brain research. Developmental brain research.
[2] K. Bdeir,et al. α-Defensin: Link between inflammation and atherosclerosis , 2007 .
[3] K. Bdeir,et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. , 2004, Blood.
[4] D. Cines,et al. Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. , 2005, Blood.
[5] D. Lawrence,et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.
[6] Alain Buisson,et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.
[7] D. Choi,et al. Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.
[8] P. Kochanek,et al. Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. , 1998, Acta neurochirurgica. Supplement.
[9] A. Higazi,et al. Identification of an Inhibitor of Tissue-type Plasminogen Activator-mediated Fibrinolysis in Human Neutrophils , 1995, The Journal of Biological Chemistry.
[10] M. Chopp,et al. Intravenous Administration of Human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats , 2001, Stroke.
[11] S. Lipton,et al. Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.
[12] D. Cines,et al. LRP and αvβ3 mediate tPA activation of smooth muscle cells , 2006 .
[13] Y. Katayama,et al. Hemorrhagic Transformation After Fibrinolysis With Tissue Plasminogen Activator: Evaluation of Role of Hypertension With Rat Thromboembolic Stroke Model , 2001, Stroke.
[14] E. Goldsmith,et al. Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.
[15] R. Huber,et al. Lysine 156 promotes the anomalous proenzyme activity of tPA: X‐ray crystal structure of single‐chain human tPA , 1997, The EMBO journal.
[16] P. Carmeliet,et al. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. , 1999, Circulation.
[17] M. Llinás,et al. Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. , 1991, Journal of molecular biology.
[18] J. Geiger,et al. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease , 2008, Journal of Neuroinflammation.
[19] Roman A Laskowski,et al. Structural quality assurance. , 2003, Methods of biochemical analysis.
[20] Jack Snoeyink,et al. Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .
[21] A. Al-Mehdi,et al. Urokinase‐derived peptides regulate vascular smooth muscle contraction in vitro and in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] J L Sussman,et al. Protein Data Bank archives of three-dimensional macromolecular structures. , 1997, Methods in enzymology.
[23] B. Winblad,et al. Blood-brain barrier in Alzheimer dementia and in non-demented elderly , 1987, Acta Neuropathologica.
[25] E. Goldsmith,et al. Restoration of serine protease-inhibitor interaction by protein engineering. , 1990, The Journal of biological chemistry.
[26] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[27] M. Sabel,et al. Locoregional opening of the rodent blood–brain barrier for paclitaxel using Nd:YAG laser‐induced thermo therapy: A new concept of adjuvant glioma therapy? , 2003, Lasers in surgery and medicine.
[28] J. Ryu,et al. A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.
[29] T. Coleman,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Neuroserpin reduces cerebral infarct volume and protects neurons from , 2022 .
[30] Douglas H. Smith,et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA , 2006, Nature Neuroscience.
[31] E. Goldsmith,et al. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition , 1995, Nature Structural Biology.
[32] E. Goldsmith,et al. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] Ulf Eriksson,et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.
[34] D. Cines,et al. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. , 1998, Blood.
[35] C. Siao,et al. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma , 2001, Neuroreport.
[36] C. Rosen,et al. Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion , 2009, Brain Research.